GSK180
Modify Date: 2025-08-25 20:24:52
GSK180 structure
|
Common Name | GSK180 | ||
|---|---|---|---|---|
| CAS Number | 1799725-26-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GSK180GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition[1]. |
| Name | 3-(5,6-dichloro-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: ~6 nM (KMO)[1] |
| In Vitro | GSK180 inhibits endogenous KMO activity in primary human hepatocytes (IC50=2.6 µM). GSK180 inhibits rat KMO slightly less potently than the human enzyme (IC50=7 µM)[1]. |
| In Vivo | GSK180 is proper for i.v. administration[1]. |
| References |
| No Any Chemical & Physical Properties |
| GSK180 |